CRISPR-Tweaked donor cells take on Hard-to-Treat blood cancers

NCT ID NCT04035434

Terminated Disease control Sponsor: CRISPR Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aimed to check safety and how well the treatment works, but it was stopped early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CTX110 (CRISPR-edited donor immune cells targeting CD19)
What this could lead to: If successful, this could point toward a readily available 'off-the-shelf' cell therapy for certain blood cancers, reducing the need for patient-specific treatments.
What could go wrong: The trial was terminated early, so data is limited. As an early-phase study, safety and effectiveness are not yet proven, and there are risks like graft-versus-host disease and severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell adult acute lymphocytic leukemia B-cell neoplasm Burkitt lymphoma leukemia lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT B CELL ALL B CELL LYMPHOMA B-CELL MALIGNANCY NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
CHU de Lille

Lille, 59000, France
Cedars Sinai

Los Angeles, California, 90048, United States
Clinica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Duke University

Durham, North Carolina, 27710, United States
Emory University Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

Dallas, Texas, 75390, United States
Hospital Clínic de Barcelona

Barcelona, 08036, Spain
Hospital Universitario de Salamanca

Salamanca, 37007, Spain
Hôpital Saint Antoine

Paris, 75012, France
Institut Paoli-Calmettes

Marseille, 13009, France
Markey Cancer Center, University of Kentucky

Lexington, Kentucky, 40536, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Roswell Park Cancer Insitute

Buffalo, New York, 14203, United States
Royal Prince Alfred Hospital

Sydney, New South Wales, 2050, Australia
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
Swedish Cancer Institute

Seattle, Washington, 98104, United States
Texas Transplant Institute

San Antonio, Texas, 78229, United States
UCSF Medical Center

San Francisco, California, 94143, United States
University Hospital Würzburg

Würzburg, 97080, Germany
University of Chicago

Chicago, Illinois, 60637, United States
University of Hamburg

Hamburg, 20148, Germany
University of Kansas

Westwood, Kansas, 66205, United States
University of Maryland

Baltimore, Maryland, 21201, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States
Virginia Commonwealth University Massey Cancer Center

Richmond, Virginia, 23298, United States
Washington University

St Louis, Missouri, 63130, United States
Weill Cornell Medical College / New York Presbyterian Hospital

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.